

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

(1) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (each, a “**Director**” and collectively, the “**Directors**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that Ms. Zhao Wei (“**Ms. Zhao**”) has been appointed as a non-executive Director and a member of the remuneration committee of the Board (the “**Remuneration Committee**”) with effect from June 30, 2025 (the “**Effective Date**”).

Ms. Zhao Wei (趙瑋), aged 46, received her bachelor’s degree of science with a major in business and finance in English from Shanghai Jiao Tong University in July 2001 and a master’s degree of business administration from The University of Hong Kong in November 2013. Ms. Zhao is a non-practising member of the Chinese Institute of Certified Public Accountants. She is currently the managing director, Corporate Development and Investments of WuXi AppTec (Shanghai) Co., Ltd., and she is mainly responsible for sourcing, evaluating, executing and integrating its strategic acquisitions, investments and joint ventures. Ms. Zhao worked at Ernst & Young Hua Ming Shanghai Branch (“**EY Shanghai**”) from September 2001 to April 2008. From February 2006 to April 2006, she briefly left EY Shanghai and worked for Deloitte & Touche Corporation Finance Ltd. Later, from May 2008 to November 2014, she worked at Ernst & Young (China) Advisory Limited. From March 20, 2019 to June 11, 2025, Ms. Zhao was a non-executive director of Clarity Medical Group Holding Limited (stock code 1406). From March 16, 2022 to October 12, 2023, Ms. Zhao was a non-executive director of Hua Medicine (stock code: 2552).

The Company will enter into a service agreement with Ms. Zhao in relation to her appointment as a non-executive Director. Ms. Zhao will hold office from the Effective Date until the next annual general meeting of the Company, at which she will be eligible for re-election in accordance with and subject to the Memorandum and the Articles of Association of the Company (the “**Articles of Association**”). Upon being re-elected thereof, her appointment shall continue for a period of three years and until the

conclusion of the annual general meeting of the Company after the re-election, or such earlier date pursuant to the Articles of Association. Ms. Zhao will receive no remunerations as director's fee, but she may be entitled to other benefits as may be determined by the Remuneration Committee having regard to the Company's and her performance, subject to review by the Company from time to time pursuant to the Articles of Association.

Save as disclosed above, Ms. Zhao confirmed that, (i) she does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) she does not hold any other major appointment or professional qualification; (iii) she has no relationship with any Directors, senior management or substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") of the Company, nor does she hold any other positions with the Company or any of its subsidiaries; and (iv) she is not interested or deemed to be interested in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information in relation to the appointment of Ms. Zhao that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters concerning the appointment of Ms. Zhao that should be brought to the attention of the shareholders of the Company or the Stock Exchange.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board announces that Ms. Zhao has been appointed as a member of the Remuneration Committee, with effect from the Effective Date. Following Ms. Zhao's appointment, the members of the Remuneration Committee are Dr. Richard James Gregory (chairperson), Ms. Zhao Wei and Dr. Lan Hu. Therefore, the requirement under the terms of reference of the Remuneration Committee to have three members in the Remuneration Committee has been satisfied.

The Board further announces that in order to comply with the requirement to have one director of a different gender in the nomination and corporate governance committee of the Board (the "**Nomination and Corporate Governance Committee**") under the revised Corporate Governance Code as set out in Appendix C1 to the Listing Rules, Dr. Richard James Gregory has resigned as a member of the Nomination and Corporate Governance Committee and Dr. Lan Hu, a female independent non-executive Director, has been appointed as a member of the Nomination and Corporate Governance Committee with effect from the Effective Date. Following such changes, the members of the Nomination and Corporate Governance Committee are Dr. James Qun Xue (chairperson), Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu.

The Board takes this opportunity to welcome Ms. Zhao and Dr. Lan Hu on their new appointments.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, June 30, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei as non-executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.